Global Targeted Cancer Therapies Market Growth Accelerated by Increasing Application of Targeted Cancer Therapies
Targeted cancer therapies provide therapeutic options to patients suffering from cancer. These therapies specifically target molecular changes in cancer cells that help them grow, divide, and spread. They work by targeting specific vulnerabilities within tumor cells. Some of the key targeted cancer therapies include monoclonal antibodies, tyrosine kinase inhibitors, and agents targeting programmed cell death protein 1 and its ligand. The global Targeted Cancer Therapies Market is estimated to be valued at US$ 1603.7 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing application of targeted cancer therapies across different cancer types is expected to drive the market growth over the forecast period. Unlike traditional chemotherapy, targeted cancer therapies are designed to interfere with specific molecular changes that allow cancer to grow. This improves the efficacy of treatment and also reduces side effects associated with non-targeted chemotherapy. With advancements in understanding of cancer biology, more molecular targets are being identified which can be blocked by targeted therapies. This is further increasing the application of targeted therapies in treatment of cancers like lung cancer, breast cancer, prostate cancer and others. The development of effective targeted therapies designed for specific cancer mutations will remain an area of active research.
Segment Analysis
Targeted cancer therapies market is dominated by monoclonal antibodies sub segment. Monoclonal antibodies accounted for over 45% of the total targeted cancer therapies market in 2023. Monoclonal antibodies are specific immune proteins designed to recognize and attach to cancer cells. They can be designed to attack cancer cells more precisely than chemotherapy or regular antibodies. Their specificity helps minimize damage to healthy tissues. This make monoclonal antibodies an attractive and dominating treatment options for targeted cancer therapies.
Key Takeaways
The Global Targeted Cancer Therapies Market Size is expected to witness high growth over the forecast period of 2023 to 2030. Regional analysis related content comprises Asia Pacific is expected to be the fastest growing region in the targeted cancer therapies market. Increasing prevalence of cancer, rising healthcare spending, growing awareness about cancer treatment are some key factors driving the growth of targeted cancer therapies market in Asia Pacific region.
Key players operating in the targeted cancer therapies market are Amgen Inc., AstraZeneca PLC, Bayer AG, Johnson and Johnson and Merck & Co. Inc. These companies accounted for over 60% share of the global targeted cancer therapies market in 2023.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/targeted-cancer-therapies-market-share-and-demand-analysis/
Comments
Post a Comment